SCIB1 Plus Nivolumab/Ipilimumab Generates ORR of 85% in Advanced Unresectable Melanoma
SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.
SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.
The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.
Katie S. Gatwood, PharmD, BCOP, explains next steps with novel agents in the hematologic oncology field that have the potential to change practice.
An artificial intelligence-based navigation tool may be used to call patients who previously missed their colonoscopy appointment with the goal that they will reschedule and…
Adding abemaciclib to fulvestrant improved PFS in patients with HR+, HER2- advanced breast cancer whose disease progressed on prior treatment with a CDK4/6 inhibitor.
Sarcomas are a broad group of cancers that originate from connective tissues, such as the blood or lymph vessels, gastrointestinal tract, fat tissue, tendons, smooth…
In all MIBC patients who received an avelumab regimen as neoadjuvant therapy, achieving a pCR was associated with longer OS.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible…
MD Anderson’s Cancerwise podcast will feature insights from our experts on cancer diagnosis and treatment, research breakthroughs, and prevention, as well as stories from survivors…
Stephen V. Liu, MD, details the phase 1/2 ARROS-1 study evaluating the selective ROS1 inhibitor zidesamtinib in patients with ROS1 fusion–positive non–small cell lung cancer.